This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association CI
North American Morning Briefing : Stocks Set for -2- DJ
Transcript : Travere Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM
Travere Therapeutics Files Supplemental New Drug Application for Filspari to Treat IgA nephropathy MT
Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI for Treatment of IgA Nephropathy CI
Travere Therapeutics Says EMA Committee Recommends Approval of Sparsentan to Treat Kidney Disease MT
Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy CI
Travere drug for rare kidney condition recommended for EU approval RE
Transcript : Travere Therapeutics, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q4 Revenue $45.1M, vs. Street Est of $41.8M MT
Travere Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Wedbush Lifts Travere Therapeutics' Price Target to $13 From $12, Keeps Outperform Rating MT
Sector Update: Health Care Stocks Mixed Premarket Friday MT
Travere Therapeutics Signs Licensing Agreement With Renalys Pharma for Rare Kidney Disease Therapy MT
Travere Therapeutics, Inc. Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations CI
Transcript : Travere Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:45 PM
Travere Therapeutics Expects $40 Million in Q4 Net Product Sales MT
Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023 CI
Travere Therapeutics, Inc. Announces Program Updates and Anticipated 2024 Milestones CI
Stifel Adjusts Price Target on Travere Therapeutics to $10 From $8, Maintains Hold Rating MT
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria CI
North American Morning Briefing : Stock Futures -2- DJ
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday MT
Sector Update: Health Care MT
Citigroup Upgrades Travere Therapeutics to Buy From Neutral, Raises Price Target to $10 From $7 MT
Chart Travere Therapeutics, Inc.
More charts
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
6.32 USD
Average target price
14.8 USD
Spread / Average Target
+134.18%
Consensus
  1. Stock Market
  2. Equities
  3. TVTX Stock
  4. News Travere Therapeutics, Inc.
  5. Sector Update: Health Care Stocks Steady Pre-Bell Tuesday